Treatment paradigms with epidermal growth factor receptor-targeted therapies in colorectal cancer

Clinical Colorectal Cancer
Stacey SteinHoward S Hochster

Abstract

Epidermal growth factor receptor (EGFR) has been validated as an important target in the treatment of metastatic colorectal cancer (mCRC). While initial studies focused on the treatment of disease that was refractory to available chemotherapy agents, 2 recent themes have emerged: the use of KRAS mutation status to select those who will benefit from anti-EGFR therapy, and the movement of these agents to earlier "lines" of therapy. We review the use of the EGFR-targeted monoclonal antibodies cetuximab and panitumumab in mCRC including the incorporation of KRAS testing in patients, and also review the use of prophylactic therapy for skin toxicity associated with EGFR-targeted therapies.

References

Jul 19, 2001·Journal of the National Cancer Institute·A A Adjei
Sep 5, 2001·British Journal of Cancer·H J AndreyevN Urosevic
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzRobert J Mayer
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Dec 5, 2006·Journal of the American Academy of Dermatology·Jenny C HuMelvin W Chiu
Feb 23, 2007·Current Opinion in Cell Biology·Erez M Bublil, Yosef Yarden
May 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemRafael G Amado
Sep 19, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzHelen X Chen
Nov 16, 2007·The New England Journal of Medicine·Derek J JonkerMalcolm J Moore
Nov 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Josep TaberneroAimery de Gramont
Dec 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alon ScopeAllan C Halpern
Mar 5, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rafael G AmadoDavid D Chang
Apr 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alberto F SobreroHoward A Burris
Oct 24, 2008·The New England Journal of Medicine·Christos S KarapetisJohn R Zalcberg
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carsten BokemeyerPiotr Koralewski
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J Randolph HechtRafael G Amado
Feb 7, 2009·The New England Journal of Medicine·Jolien TolCornelis J A Punt
Apr 3, 2009·The New England Journal of Medicine·Eric Van CutsemPhilippe Rougier
May 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott KopetzRobert R McWilliams
May 29, 2009·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre Laurent-PuigFrédérique Penault-Llorca
Oct 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marc PeetersJennifer Gansert

❮ Previous
Next ❯

Citations

Dec 3, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Marko KornmannKarl-Heinrich Link
Jan 1, 2012·American Society of Clinical Oncology Educational Book·Thierry AndréJeffrey A Meyerhardt

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.